Baicalin — drug repurposing hypotheses

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

Baicalin appears in hypotheses across 5 disease domains: Alzheimer, Depression, Inflammatory bowel disease, Multiple sclerosis, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: BDNF.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for Baicalin

Alzheimer 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
BDNF	Alzheimer's disease	0.269	Mid	reproduces known	none

Depression 14

Mediator	Outcome	Score	Tier	Lit. status	Trial
BDNF	schizophrenia	0.312	High	partial evidence	none
BDNF	major depressive disorder	0.269	Mid	partial evidence	none
BDNF	bipolar disorder	0.269	Mid	novel signal	none
BDNF	depression severity	0.269	Mid	novel signal	none
BDNF	remission	0.208	Mid	reproduces known	none
BDNF	suicide risk	0.208	Mid	novel signal	none
BDNF	anhedonia	0.208	Mid	partial evidence	none
BDNF	major depression	0.208	Mid	partial evidence	none
BDNF	neurogenesis	0.208	Mid	reproduces known	none
BDNF	depressive disorder	0.208	Mid	reproduces known	none
BDNF	visuospatial ability	0.208	Mid	novel signal	none
BDNF	remission	0.208	Mid	reproduces known	none
BDNF	improvement in depressive symptoms	0.208	Mid	novel signal	none
BDNF	oxidative stress	0.208	Mid	reproduces known	none

Inflammatory bowel disease 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
BDNF	cell viability	0.208	Mid	reproduces known	none

Multiple sclerosis 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
BDNF	Multiple Sclerosis	0.208	Mid	partial evidence	none

Rheumatoid arthritis 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
sirtuin-1	rheumatoid arthritis	0.208	Mid	reproduces known	none

← All drugs